{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-033697","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.524136+00:00","generated_at":"2026-06-06T03:33:41.934608+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Metagenomi adopts amended charter and bylaws in connection with IPO","bullets":["Authorized 500M shares of common stock and 10M shares of undesignated preferred stock.","Eliminated all references to prior series of preferred stock.","Stockholders can no longer act by written consent or call special meetings.","Established advance notice procedures for stockholder proposals and director nominations.","Amendments effective upon consummation of the initial public offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-033697","json":"https://secwatch.observer/filing/0001193125-24-033697.json","markdown":"https://secwatch.observer/filing/0001193125-24-033697.md","text":"https://secwatch.observer/filing/0001193125-24-033697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312524033697/0001193125-24-033697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312524033697/d770467d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:33:41.934608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9b0b87e0ac84a7544b5c497ac7f3352ce077d0e","claim":"Metagenomi Therapeutics, Inc.: Amended and restated bylaws to eliminate stockholder written consent and special meeting ability, establish advance notice procedures for stockholder proposals and director nominations, and conform to the restated certificate.","evidence_excerpt":"the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders to become effective immediately upon effectiveness of the Registration Statement, became effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312524033697/0001193125-24-033697-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"e89160eac0cc9b6f56816ec0201ecad13d211851","claim":"Metagenomi Therapeutics, Inc.: Filed amended and restated certificate of incorporation to authorize 500,000,000 shares of common stock, eliminate references to existing preferred stock, and authorize 10,000,000 shares of undesignated preferred stock.","evidence_excerpt":"the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312524033697/0001193125-24-033697-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}